Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL Trial (BOOG 2006-05). J Natl Cancer Inst 2018; 110: 40-48.

Published: 9th August 2018

Authors: Blok EJ, Kroep JR, Kranenbarg EM-K, Duijm-de Carpentier M, Putter H, van den Bosch J et al.


There was no advantage to the longer course of letrozole in the study of 1824 women. Five year disease-free survival (hazard ratio 0.92, 95 per cent confidence interval 0.74 to 1.16) and overall survival rates (1.04, 0.78 to 1.38) were similar.

Pubmed Link

Your comments